Ladder Bio Inc.

Ladder Bio Inc. , based in the US, specializes in research and development of innovative Spiroligomer™ molecules designed for precise molecular interactions in therapeutics and diagnostics. Founded in 2020 and headquartered in Blue Bell, US, Ladder Bio Inc. is focused on creating advanced molecular solutions for drug discovery and diagnostics.

The company received USD 5. 5 million in Seed funding in September 2025, led by Medical Excellence Capital, with participation from Hatch BioFund Management. Ladder Bio Inc. specializes in developing Spiroligomer™ molecules, which are a new class of synthetic structures engineered for specific binding to proteins.

These molecules aim to provide targeted therapeutic and diagnostic applications with reduced off-target effects. Their technology offers benefits such as stability, cell permeability, and non-immunogenicity, appealing to pharmaceutical companies and diagnostic labs primarily in North America and Europe. Ladder Bio’s revenue model is structured around partnerships with pharmaceutical companies and diagnostic firms, utilizing licensing agreements and research collaborations. Clients typically provide upfront fees and milestone payments for developmental achievements, along with royalties from commercialized products.

The firm's main offering, Spiroligomer™, is key to attracting clients focused on innovative drug discovery. Following the recent funding of USD 5. 5 mn in September 2025, Ladder Bio Inc. plans to enhance its Spiroligomer programs and conduct laboratory studies.

The funding will also be allocated to hiring additional staff for chemistry and biology research. The company aims to expand its market reach further into North America and Europe, capitalizing on the growing demand for advanced therapeutic modalities and diagnostic tools.